Unlike Keryx, Acadia's stock (the orange line) kept pace with the Nasdaq Biotech Index. In April, Acadia zoomed and has since outperformed the broader biotech sector. What happened in April? That's when Acadia announced plans to seek FDA approval for pimavanserin based on the phase III data in hand. Before this, it was thought Acadia would need to run another, confirmatory study before seeking FDA approval.
The big difference between Acadia and Keryx is there is no debate about the patents or market exclusivity for pimavanserin. The FDA is widely expected to grant pimavanserin five years of market exclusivity as an NCE, and with that designation and the patents, investors are more confident that Acadia can land a Big Pharma marketing partner or be acquired.
The lesson here: Patents and market exclusivity matter -- a lot. Acadia has both, Keryx and Amarin do not. The results are reflected in the performance of their respective stocks.-- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV